SEC Tracker
Get the app

Eterna Therapeutics ERNA

Eterna Therapeutics Q1 FY24: revenue $47K; diluted EPS −$1.23

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Eterna Therapeutics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$47KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$6.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$1.23No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$3.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Eterna Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Marker Therapeutics MRKR public float $17M, Jun 30, 2025
  2. Charlie's Holdings CHUC public float $18M, Jun 30, 2025
  3. Cognition Therapeutics CGTX public float $18M, Jun 30, 2025
  4. IGC Pharma IGC public float $18M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025